Bing Lim, MD, PhD, is the Chief Scientific Officer at Thymmune Therapeutics with expertise in drug discovery and cell therapy. During his tenure as the Senior Vice President for Cell Therapy at Sana Biotechnology, he led efforts in differentiating, manipulating, and transplanting human stem cells to develop regenerative therapies. With 27 years as a principal investigator at Harvard Medical School and the Genome Institute of Singapore, his laboratory contributed significantly to stem cell differentiation and cellular transdifferentiation methods, identified molecular regulators of pluripotency, and discovered markers and therapeutic targets for human tumor-initiating cells.